SEC Contract Filing

Filing Date: 2015-07-02

Document Content:
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>f8k062615ex10ii_xrproscien.htm
<DESCRIPTION>MASTER SERVICES AGREEMENT
<TEXT>
<HTML>
<HEAD>
 <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0"><B>Exhibit 10.2</B></P>

<P STYLE="margin-top: 0; text-align: justify; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: justify; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Portions
herein identified by XXXX have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.&nbsp;&nbsp;A complete copy of this document has been filed separately with the Securities and
Exchange Commission.</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>MASTER
SCIENTIFIC SERVICES AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
Services Agreement (&ldquo;Agreement&rdquo;) is made as of this 1<SUP>st</SUP> July 2015 (the &ldquo;Effective Date&rdquo;) by
and between <B>XRPRO SCIENCES INC.</B>, a Delaware corporation, having an address of One Kendall Square, Suite B2002, Cambridge,
Massachusetts 02139 (&ldquo;Provider&rdquo;) and <B>PFIZER INC.</B>, a Delaware corporation, having an address of 235 East 42<SUP>nd
</SUP>Street, New York, New York 10017 (&ldquo;Pfizer&rdquo; or the &ldquo;Company&rdquo;). Provider and Pfizer may be referred
to in this Agreement individually as a &ldquo;Party&rdquo; or collectively as the &ldquo;Parties&rdquo;.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="text-transform: uppercase"><U>Definitions</U></FONT></B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Affiliate(s)&rdquo;
means, with respect to each Party, any person which directly or indirectly controls or is controlled by or is under common control
with that Party. For purposes of this definition, &ldquo;control&rdquo; (including, with correlative meaning, the terms &ldquo;controlled
by&rdquo; and &ldquo;under common control with&rdquo;) shall be presumed to exist if one of the following conditions is met: (a)
in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having
the right to vote for the election of directors of Party or any direct or indirect parent of Party, and (b) in the case of non-corporate
entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management
and policies of such non-corporate entities.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Change
of Control&rdquo; means any transaction resulting in the sale or transfer of (a) all or substantially all of the assets of Provider,
(b) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having
the right to vote for the election of directors of Provider or any direct or indirect parent of Provider, or (c) in the case of
non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to
direct the management and policies of such non-corporate entities.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.15pt">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;Pfizer
Confidential Information&rdquo; means <FONT STYLE="letter-spacing: -0.15pt">all information disclosed to Provider or its Personnel
by or on behalf of Pfizer or learned or observed by Provider or its Personnel relating to (i) Pfizer&rsquo;s business or business
plans, including, without limitation, current status, data, compounds, targets, structures, methods of analysis, study protocols
or any other information regarding Pfizer&rsquo;s operations and research and development programs, suppliers, customers, prospective
customers, contractors, clinical data, the content and format of various research, clinical and medical databases, utilization
data, cost and pricing data, disease management data, software products, programming techniques, data warehouse and methodologies,
all proprietary information, know-how, trade secrets, technical and non-technica